Dealbreaker on MSN16h
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.
FiercePharma4d
Once valued at $10B, bluebird bio sold to private equity firms for $29M
That’s what Carlyle and SK Capital are paying for the 15-year-old Massachusetts biotech in a deal that was announced on Friday. There is a catch. If the private equity firms can boost sales of ...
Reuters4d
Gene therapy maker bluebird to go private in discounted deal amid cash crunch
Feb 21 (Reuters) - Gene therapy maker bluebird bio (BLUE.O), opens new tab on Friday agreed to be taken private by Carlyle Group (CG.O), opens new tab and SK Capital Partners at a discount ...
Nasdaq3d
Bluebird Bio To Be Taken Private By Carlyle And SK Capital Partners
Carlyle and SK Capital will provide bluebird primary capital to scale bluebird's commercial delivery of gene therapies for patients with sickle cell disease, ß-thalassemia, and cerebral ...
The Boston Globe4d
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered ...